Mineralys Therapeutics had its Relative Strength (RS) Rating upgraded from 72 to 91 Monday.
This exclusive rating from Investor's Business Daily tracks share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an RS Rating north of 80 at the beginning of a new price run.
Here Are 3 Keys For Successful Stock Investing
Mineralys Therapeutics is not currently showing a potential entry point. See if the stock goes on to form a chart pattern that could launch a new move.
The company showed 0% earnings growth last quarter. Sales gains came in at 0%.
Mineralys Therapeutics earns the No. 118 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
